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Alopecia areata, a disease of the hair follicles with multifactorial etiology and a strong component of autoimmune origin, has been
extensively studied as far as the role of several cytokines is concerned. So far, IFN-γ, interleukins, TNF-α, are cytokines that are
well known to play a major role in the pathogenesis of the disease, while several studies have shown that many more pathways
exist. Among them, MIG, IP-10, BAFF, HLA antigens, MIG, as well as stress hormones are implicated in disease onset and activity.
Within the scope of this paper, the authors attempt to shed light upon the complexity of alopecia areata underlying mechanisms
and indicate pathways that may suggest future treatments.
1.Introduction
Alopecia areata is a disease of the anagen stage hair follicles,
considered to be autoimmune in origin. Prevalence in the
general population is between 1% and 2% [1] and it
can occur at any age. Alopecia areata is characterized by
either patchy hair loss or more generalized alopecia that
results in complete loss of scalp hair (alopecia totalis). The
presence of atopy and the onset in prepubertal children
indicates poor prognosis [2]. The histopathologic features
of the disease consist of perifollicular lymphocytic inﬁltrates
around anagen hair follicles, consisting of both CD4+ and
intrafollicular inﬁltrates of CD8+ cells. Several studies have
shown that within the cascade of pathogenesis of alopecia
areata,cytokinesandothermoleculesthatcoordinatecyclical
hair growth play a crucial role. In this paper, we attempt to
review the role of some of the most important cytokines,
along with other mediators in alopecia areata, and indicate
pathway routes that may be target therapies in the future.
2. IFN-γ
IFN-γ is themaincytokine known tobe aberrantly expressed
in alopecia areata through a CD4+ Th1 mediated response.
IFN-γ is produced by perifollicular or follicular antigen
presenting cells and among several actions it also deprives
dermal papilla cells of their ability to maintain anagen
hair growth, as shown in human studies [3]. It has been
shown that serum levels of IFN-γ are signiﬁcantly higher
in patients with alopecia totalis or alopecia universalis
compared to controls, but no signiﬁcant diﬀerence has been
found in levels of IFN-γ between patients with localized
alopecia areata and those with more extensive forms [4].
Additionally, experiments in human alopecia areata by
Deeths et al. show that antigen speciﬁc T-cells from patients
with extensive disease appear to have some intrinsic defect
towards production of IFN-γ, possibly suggesting a state of
partial tolerance in the skin of these patients [5]. Despite the
above, the elevated serum levels of IFN-γ in alopecia areata
patients may reﬂect the state of inﬂammation, especially in
the extensive forms of the disease, and the measurement
of serum IFN-γ may be useful in discriminating those who
are likely to develop alopecia universalis from the remaining
local disease, or as a prognostic indicator. It is suggested that
future studies may be able to evaluate the evolution of IFN-γ
levels in patients with spontaneous regression or progressive
extension of the disease [4].
MIG (monokine induced by IFN-γ) is a cytokine that
is elevated in human alopecia areata and its level correlates
withdiseaseactivity,increasinginexpandinglesionsandvice2 Mediators of Inﬂammation
versa, making it a useful marker of monitoring of the disease
status and response to treatment [6]. MIG mRNA is mostly
found in mononuclear cells in the peri- and intrabulbar
inﬁltrate and also in the follicular papilla. Also, another
chemokineleadingtorecruitmentofmononuclearcellsisIP-
10 (interferon inducible protein-10), which is also induced
by IFN-γ. Experiment in IP-10 is much less expressed
compared to MIG but accounts for the persistence of Th1
response in alopecia areata, perpetuating the recruitment of
lymphocytes [7].
3.Interleukins
Studies have shown that IL-1 is a very potent inducer of
hair loss and a signiﬁcant human hair growth inhibitor in
vitro. Hoﬀman et al. have demonstrated that during induced
murine hair cycle, IL-1α and IL-1β increase profoundly
with the onset of spontaneous catagen phase, while they
peak during telogen phase and are associated with increased
expression of the signal transducing type I IL-1 receptor [8].
Additionally, according to studies by Groves et al., transgenic
mice overexpressing IL-1a in the epidermis have patchy hair
loss resembling alopecia areata [9].
In human scalp areas aﬀected by alopecia areata, an
excessive expression of IL-1β is detected particularly at the
early stages of the disease, while susceptibility to the disease
and severity are determined by polymorphisms of the IL-1-
receptor antagonist and IL-1a. In terms of clinical severity, a
more progressive expression of the disease is encountered in
patients, who, due to gene polymorphisms, have insuﬃcient
amounts of IL-1 receptor antagonist, the natural antagonist
of IL-1 [10], while an increased frequency of the allele 2 of
the IL-1 receptor antagonist gene was found in patients with
e x t e n s i v eA Ah a i rl o s s[ 11]. Experiments in cultured hair
follicles by Philpott et al. showed that the eﬀects of IL1-α
and IL1-β on them may be blocked by addition of the IL-
1 receptor antagonist [12]. Also, IL-1 gene polymorphisms
may be responsible for exaggerated release of IL-1, leading
to rapid and more progressive disease [13]. Galbraith et al.
showed that patients with severe forms of alopecia areata
have an increased frequency of the IL-1β 1,2 genotype [14],
with allele 2 of the IL-1β +3953 polymorphism exhibiting a
strong association with increased production of IL-1β [15].
In the same study it was found that IL-1β loci along with
loci of immunoglobulin κ light chain act cooperatively to
signiﬁcantly increase susceptibility to the disease [14].
Serum levels of IL-1α and IL-4 are signiﬁcantly elevated
inpatientswithlocalizedalopeciaareata,whileIL-2andIFN-
γ are mainly elevated in extensive disease states, possibly
implying that the progression to the extensive form may
be mediated by Th1 cytokines [16]. It is also considered
that a disequilibrium in the production of cytokines, with
a relative excess of proinﬂammatory and Th1 types, versus
antiinﬂammatory cytokines, such as IL-4 and IL-10 may
be involved in the persistence of alopecia areata lesions, as
shown in human scalp biopsies [17]. Finally, in agreement
withabove,ithasbeenshownthatsteady-statelevelsofIL-10
mRNA increase after successful DCP treatment, making IL-
10 an important inhibitor of Th1 cytokine production [18].
4. TNF-α
TNF-α is well known to play a major role in the pathogenesis
of alopecia areata. TNF-α is synthesized in epidermal
keratinocytes along with several other cytokines [19] and is
known to be a very potent inhibitor of proliferation [20].
In vitro studies have shown that TNF-α, along with IL-
1α and IL1-β, causes vacuolation of matrix cells within the
follicle bulb and a decrease in the size of the matrix, as well
as disorganization of follicular melanocytes and abnormal
diﬀerentiation and keratinization of the precortical cells and
the inner root sheath [12]. TNF-α levels in the skin correlate
positively with plasma ACTH levels and cutaneous ACTH
receptor expression levels under repeated stress in humans
[21], possibly suggesting a pathophysiologic mechanism
lying behind the well-known role of stressors in alopecia
areata.
Theseraofpatientswithalopeciaareataandinparticular,
the subgroup of patients with multiple lesions, have been
found to contain extremely high levels of BAFF, namely,
B cell activating factor that belongs to the TNF family,
produced by myeloid lineage cells [22]. It is considered
that the production of BAFF is stimulated by IFN-γ that
is well known to be increased in alopecia areata patients,
as mentioned above [23]. Experiments in mice have shown
that BAFF may also activate T-cells and thus promote
Th1 response, leading to the production of IFN-γ and
perpetuation of disease activity [24].
5. Major HistocompatibilityComplex (MHC)
andFas-Antigen
The hair follicle is a frequent target of immune-mediated
tissue injury, leading to development of alopecia areata.
Under normal conditions, the hair follicle is considered an
area of relative immune privilege during the anagen stage
of hair growth. Thus, autoantigens are not recognized by
CD8+ T-cells, allowing normal hair growth. MHC class I
antigens demonstrate very low expression during this phase,
something which is mediated by locally produced cytokines,
such as TGF-b1, ACTH, a-MSH, and IGF-1, all of which
serve as very potent immunosuppressants, produced by
anagen hair bulbs [25]. Also, anagen hair bulbs show very
few antigen-presenting cells that appear to be functionally
impaired since they do not express MHC class II antigens
[26].
Alopecia areata lesions can be induced in mice by the
transfer of MHC class I restricted CD8+ T-cells alone,
while anagen hair follicle antigens are essential for T-
cell stimulation that ends up in the development of the
disease [27]. CD8+ cells are of crucial importance in AA,
by interacting with MHC-I restricted autoantigens and
inducing cytolysis of target cells [10]. Several triggers, such
as emotional factors, skin microtrauma, or infectious agents
aided by a possible underlying immune predisposition, leadMediators of Inﬂammation 3
to intrafollicular rise in IFN-γ, that causes MHC class Ia
upregulation in the proximal hair follicle epithelium [25].
Also, HLA class II antigens and ICAM-1, both implicated
in lymphocyte traﬃcking and antigen presentation, increase
their expression in response to stimuli by IFN-γ and TNF-α
in cultured hair follicles [28].
Fas-antigen belongs to a nerve growth/TNF receptor
superfamily and it is a membrane protein involved in
apoptosis. It is considered that the abnormal expression
of Fas-antigen on hair follicles keratinocytes may play an
important role in alopecia areata [17].
6. The Role of Mononuclear Cells
The regulatory role of peripheral blood mononuclear cells
(PBMCs) has been clearly elucidated through the work of
Z¨ oller et al. It has been found that active alopecia areata
patients’ PBMCs display increased resistance towards apop-
tosis. This is considered to be sustained by downregulation
of CD95L+ and increase in CD44v7+, both known to be
associated with antiapoptotic gene expression. PBMC from
patients with progressive alopecia areata reveal a higher per-
centage of CD4+ CD25+ CD154+ T-cells that suppress the
proliferative activity of CD8+ PBMC to a much lesser extent
when compared with CD4+ CD25+ PBMC of health donors
or patients with stable or regressive alopecia areata. In par-
ticular, it is considered that the population of CD4+ CD25+
CD154+ PBMC that express CD44v7+ is very resistant to
apoptosis and characterizes active alopecia areata [29].
7. Macrophage Migration
Inhibitory Factor (MIF)
MIF is a cytokine produced by lymphocytes and peripheral
blood mononuclear cell that may play a key role in the
pathogenesis of extensive alopecia areata. MIF was the ﬁrst
lymphokine reported to prevent the random migration of
macrophages [30]. MIF levels are signiﬁcantly elevated in
alopecia areata patients. This molecule stimulates the pro-
duction of IL-1 and TNF-a by macrophages, while the latter
exert positive feedback eﬀect on MIF. The cycle endpoint is
an on-going inhibition of hair growth [31]. Polymorphisms
within the MIF-173C allele confer an increased risk of early
onset extensive form of alopecia areata at ages below 20, as
shown in the study of Shimizu et al. [32]. Given the fact
that antibodies against MIF have shown encouraging results
in the treatment of murine hepatitis [33], MIF production
control may show promise for eﬀective treatment modalities
in extensive alopecia areata patients.
8.AlopeciaAreataandStressHormones
In alopecia areata, signiﬁcant interactions have been found
betweentheneuroendocrineandtheimmunesystem.Exper-
imental studies in mice with alopecia areata showed altered
hypothalamic-pituitary-adrenal (HPA) axis activity, possibly
secondary to altered immune response. In particular, a
marked increase in the HPA axis tone, and activity was
noted, both in central and peripheral levels in the skin
and lymph nodes, as well as a signiﬁcantly blunted ACTH
response to acute stress and repeated restraint stress [34].
Other studies showed increased ACTH and α-MSH levels
in alopecia areata patients, suggesting the presence of an
active neurogenic system and local HPA axis activity, with
positive correlations with TNF-α level, as mentioned above.
Additionally, hypothalamic arginine vasopressin mRNA and
pituitary proopiomelanocortin mRNA were found to be
elevated under acute and repeated stress conditions, also
suggesting HPA axis hyperactivity [34]. Furthermore, the
decreased hypothalamic and hippocampal expression of
estrogen receptor-β under basal and repeated stress, and the
increased expression under acute stress possibly indicate a
disrupted hypothalamic pituitary gonadal axis in alopecia
areata disease states [21]. The above may well provide a
strongevidencefortheroleofstresshormonesinmodulating
the inﬂammatory response in this category of patients.
9. Diphenylcypropenone (DCP)
The role of cytokines in the pathogenesis of alopecia areata
has been elucidated through the use of DCP, a contact
sensitizer and basic treatment modality for this disease. It
has been suggested that treatment of alopecia areata lesions
with a contact sensitizer inﬂuences leukocyte migration,
causing increase in monocytes and decrease in dendritic cell
migration towards draining nodes [35]. It is suggested that
the beneﬁcial eﬀect of DCP is mediated by locally secreted
cytokines during the contact allergy [36]. Happle et al.
have proposed the Renbok phenomenon as the opposite of
Koebner phenomenon, to describe the response of alopecia
areata diseased skin to contact sensitizers [37].
In DCP treated patients, a perifollicular inﬁltrate mainly
composed of CD8+ and CD1a cells is noted, as well as
increased expression of CD44 and CD49d. The increase in
CD1a+dendriticcellsindicateshamperingoftheemigration
of antigen presenting cells by DCP treatment, while both
CD44 and CD49d play major role in leukocyte extravasation
[38]. After successful DCP treatment the ratio of CD4 : CD8
decreases from 4 : 1 to 1 : 1 in the perifollicular inﬁltrate and
the expression of IFN-γ decreases along with decrease in IL-
1β and increases in IL-2, IL-8, IL-10, and TNF-a [6].
DCP use is associated with an elevated number of
inﬁltrating leukocytes in the bulbar and suprabulbar area
of the hair follicle, apparently newly recruited leukocytes
that act against autonomously functioning CD4+ and CD8+
cells. The above process is mediated by several cytokines,
as mentioned above, implicating that pathogenesis and
recovery form alopecia areata follow a well-programmed
pathway.
10. Discussion
A concrete hypothesis on the pathogenetic mechanisms of
alopecia areata, as it becomes evident through the role
of the above mentioned cytokines and their pathways, is
diﬃcult to be formed. It has been suggested that a T-cell4 Mediators of Inﬂammation
mediated autoimmune process is triggered by endogenous
or exogenous stimuli and maintained by the interaction
of several molecules. Probably, in genetically predisposed
individuals, under the eﬀect of stress hormones, the hair
follicleentersa cycleof autoimmune inhibition of its growth.
Although alopecia areata is considered to have immunologic
origin, neither autoimmune disorders nor autoantibodies
are more common in these patients. The pathogenetic
mechanisms so far known indicate a rather complex process
thatsustainsaninﬂammatoryreaction,thatis,aviciouscycle
which leads to hair loss. The keratinocytes release cytokines
that activate endothelial cells, which in turn attract T-cells
and macrophages that release more cytokines.
Despite the complicated pathogenesis of alopecia areata,
severalstudiesoverthelastyearshavesigniﬁcantlyattempted
and managed to throw light into the mechanisms of origin
and evolution of this entity. So far well-known cytokines,
such as TNF-α, interleukins, and IFN-γ,h a v eb e e ne x t e n -
sively studied along with many more, and possible thera-
peutic targets have been identiﬁed. Interestingly, antiTNF-
α drugs have not proven to be of use in alopecia areata.
Accordingtotherecentobservationalstudies, alopecia areata
lesions have developed in patients receiving such treatments
[39] and recurrence of disease has occurred while receiving
antiTNF-α drugs [40]. Similarly, in other dermatologic
diseases, such as psoriasis, it has been shown that antiTNF-α
may have a paradoxical adverse event, leading to the devel-
opment of psoriatic skin lesions in predisposed individuals
[41]. A suggested explanation of this failure might be that
TNF-α is just one of the ever expanding list of cytokines
involved in the pathogenesis of alopecia areata. Additionally,
in other immune-mediated inﬂammatory diseases, such
as psoriasis, where anti TNF-a agents constitute a within
label treatment, diﬀerent antiTNF-α agents display variable
eﬃcacyindiﬀerentpatients.AnantiTNF-αdrugmayalsofail
to maintain the initial good response over time, possibly due
to the development of neutralizing antibodies. Deﬁnitely, the
role of TNF-α in the pathogenesis of alopecia areata as well
as other autoimmune diseases has to be further investigated
as far as treatment with antiTNF-α agents is considered.
Nevertheless, inability to target therapeutically a single
cytokine suggests that alopecia areata is either so multifacto-
rial in its pathogenesis, or, we only see the tip of the iceberg.
Despite that, the plethora of implicated mechanisms that
potentially give onset to and maintain or increase the activity
of this disease may show promise for future treatment
modalities that will make a real diﬀerence in the lives of these
patients.
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